ATG-106 / Antengene - LARVOL DELTA

ATG-106, a novel "2+1"format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (AACR 2026) - "ATG-106 also induced tumor shrinkage and complete remission in OVCAR-3 model. ATG-106-RM was well tolerated in rhesus monkey at doses up to 10mg/kg.ConclusionsATG-106 demonstrated powerful T cell dependent cytotoxicity and in vivo anti-tumor efficacy against ovarian and renal cancer preclinically, which warrants further clinical evaluation."

Preclinical • Genito-urinary Cancer • Kidney Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • CDH6

Business Updates: AnTenGager TCE Platform (PRNewswire) - "The Company plans to submit an IND application for ATG-106 in the second quarter of 2027.... The Company plans to submit an IND application for ATG-112 in the second quarter of 2027....Antengene plans to submit an IND application for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer."

IND • Bladder Cancer • Colorectal Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Renal Cell Carcinoma

Title: ATG-106, a novel ’2+1’ format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (PRNewswire) - "Antengene to Present on...Preclinical Programs at AACR 2026....ATG-106 demonstrated reduced binding affinity to CD3-positive cells prior to CDH6 engagement while inducing significantly enhanced cytotoxic activity against CDH6-positive tumor cells compared with conventional TCE formats. In PBMC-humanized xenograft models of renal and ovarian cancer, ATG-106 induced robust tumor regression with complete responses observed in multiple treatment groups."

Preclinical • Kidney Cancer • Ovarian Cancer • Renal Cell Carcinoma

ATG-106 (CDH6 x CD3 TCE) (PRNewswire) - "A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer. The Company plans to submit an IND for ATG-106 in the first half of 2027."

IND • Kidney Cancer • Ovarian Cancer

Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs (The Malaysian Reserve) - "...it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), ATG-037 (oral CD73 small molecule inhibitor), and ATG-101 (PD-L1/4-1BB bispecific antibody). The company will also share the latest progress on ATG-125 (B7H3 x PD-L1 bispecific ADC): A B7H3 x PD-L1 targeted therapy featuring “'O + ADC' dual-effect molecules for the treatment of solid tumors and its AnTenGager™ T-cell engager (TCE) technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs."

Clinical data • Colorectal Cancer • Hematological Malignancies • Melanoma • Neuroendocrine Carcinoma • Non Small Cell Lung Cancer • Ovarian Cancer

ATG-106, a novel '2+1' format CDH6-targeted T-cell engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (SITC 2024) - "0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg ATG-106 produced significant anti-tumor efficacy with mean TGI values of 132.53%, 140.34%, and 140.23%, respectively. Complete tumor remission was observed in 0.3 mg/kg (3 out of 6 mice) and 1 mg/kg (3 out of 6 mice) treatment groups"

Preclinical • Endocrine Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • CDH2 • CDH6

Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (PRNewswire) - "Antengene Corporation Limited...announced that it will present results from...programs at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC 2024)....Abstract Number: 1069:....ATG-106, a '2+1' CDH6 x CD3 TCE, was designed to address CRS challenge by targeting CDH6 and activating T cells only in the presence of CDH6-positive cells, minimizing CRS risk. Preclinical studies showed strong binding affinity to CDH6+ cells and potent T-cell-dependent cytotoxicity. It induced lower cytokine release in vitro compared to benchmarks. In vivo studies using ovarian cancer xenograft models demonstrated that ATG-106 achieved significant tumor growth inhibition (TGI) with tumor shrinkage and complete remission observed in multiple treatment groups."

Preclinical • Ovarian Cancer

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024."

Preclinical • Acute Myelogenous Leukemia